# Appendices

Appendix A: Project Brief

Appendix B: TU Delft Ethical Approval Forms (HREC)

Appendix C: Topic modelling results

Appendix D: Final re-interpreted categories and topics

Appendix E: HPs Co-creation session set up

Appendix F: HPs Co-creation booklet

Appendix H: Results brainstorming session with designers

Appendix I: Patient validation session set up & questionnaire

# **Appendix A: Project Brief**

Procedural Checks - IDE Master Graduation

**TU**Delft

#### APPROVAL PROJECT BRIEF

To be filled in by the chair of the supervisory team.

chair Richard Goossens date 20 - 02 - 2023

Richard Richard Goosse Date:

ns - IO 2023,03,03
13,3748
401100

#### **CHECK STUDY PROGRESS**

To be filled in by the SSC E&SA (Shared Service Center, Education & Student Affairs), after approval of the project brief by the Chair. The study progress will be checked for a 2nd time just before the green light meeting.

Master electives no. of EC accumulated in total:  Of which, taking the conditional requirements into account, can be part of the exam programme		EC EC	C		st year master cours	
List of electives obtained before the third semester without approval of the BoE					◇点布签名	
name	_ date _		-	signature		

## FORMAL APPROVAL GRADUATION PROJECT

To be filled in by the Board of Examiners of IDE TU Delft. Please check the supervisory team and study the parts of the brief marked \*\*. Next, please assess, (dis)approve and sign this Project Brief, by using the criteria below.

- Does the project fit within the (MSc)-programme of the student (taking into account, if described, the activities done next to the obligatory MSc specific courses!?
- Is the level of the project challenging enough for a MSc IDE graduating student?
- Is the project expected to be doable within 100 working days/20 weeks?
- Does the composition of the supervisory team comply with the regulations and fit the assignment?

Content.		ALLINOVED	) NOT A	MITHOVED
Procedure:	$\bigcirc$	APPROVED	NOT A	APPROVED
				- comments
			◇点击签名	
		signature .		
atudu ayan ia	/// 2010	0.0120		Daga 2 of 7

Content: APPROVED NOT APPROVED

IDE TU Delft - E&SA Department /// Graduation project brief & study overview /// 2018-01 v30 Page 2 of 7
Initials & Name R. Zhang Student number 4786629

Title of Project Optimizing pulmonary fibrosis patients experience by remote monitoring

ESIGN FOR OUL PULLUYE

# TUDelft

# **IDE Master Graduation**

Project team, Procedural checks and personal Project brief

This document contains the agreements made between student and supervisory team about the student's IDE Master Graduation Project. This document can also include the involvement of an external organisation, however, it does not cover any legal employment relationship that the student and the client (might) agree upon. Next to that, this document facilitates the required procedural checks. In this document:

- The student defines the team, what he/she is going to do/deliver and how that will come about.
- · SSC E&SA (Shared Service Center, Education & Student Affairs) reports on the student's registration and study progress.
- · IDE's Board of Examiners confirms if the student is allowed to start the Graduation Project.

## USE ADOBE ACROBAT READER TO OPEN, EDIT AND SAVE THIS DOCUMENT

Download again and reopen in case you tried other software, such as Preview (Mac) or a webbrowse

## STUDENT DATA & MASTER PROGRAMME

R. given name Ruixuan

family name Zhang

street & no.	Andre Van der Louwbrug 314
zipcode & city	3011WM, Rotterdam
country	the Netherlands
phone	+31 629916771

email R. Zhang-11@student.tudelft.n

student number 4786629

Save this form according the format "IDE Master Graduation Project Brief\_familyname\_firstname\_studentnumber\_dd-mm-yyyy".

Complete all blue parts of the form and include the approved Project Brief in your Graduation Report as Appendix 1!

Your master progran		t the options tha	
IDE master(s):	() IPD	Dfl )	SPD
2 <sup>nd</sup> non-IDE master:			
individual programme:	20 - 02 - 20	23 (give da	ate of approval
honours programme:	Honours I	Programme Mast	er
specialisation / annotation:	Medisign		
	Tech. in S	Sustainable Desig	n
	Entrepene	eurship	

## SUPERVISORY TEAM \*\*

Fill in the required data for the supervisory team members. Please check the instructions on the right

** chair	Richard Goossens	dept. / section:	HCD/AED
** mentor	Judith Rietjens	dept. / section:	DOS
2 <sup>nd</sup> mentor	Jiwon Jung		
	organisation: Erasmus Medical	Center (Erasmus	MC)
	city: Rotterdam	country: the	Netherlands
comments (optional)	Addtional feedback from Man ssional: Pulmonologist, Cha ung Diseases and Sarcoidos:	air of the Centr	e for Interstitial L

Chair should request the IDE Board of Examiners for approval of a non-IDE mentor, including a motivation letter and c.v..

Second mentor only applies in case the assignment is hosted by an external organisation.

Ensure a heterogeneous team. In case you wish to include two team members from the same section, please explain why.

IDE TU Delft - E&SA Department /// Graduation project brief & study overview /// 2018-01 v30

Page 1 of 7



## Personal Project Brief - IDE Master Graduation

introduction (continued): space for image

# Current platform: IPF online IPF Online: Product-service system, collecting patients lung function data (FVC) Patients: monitoring lung function at home with a spirometer Medical Team: communication tool with patients

image / figure 1: The current product: IPF-Online




image / figure 2: \_\_An overview of the stakeholders involved

IDE TU Delft - E&SA Department /// Graduation project brief & study overview /// 2018-01 v30 Page 4 of 7
Initials & Name R. Zhang Student number 4786629

Title of Project Optimizing pulmonary fibrosis patients experience by remote monitoring

**TU**Delf

## Personal Project Brief - IDE Master Graduation

Optimizing pulmonary fibrosis patients experience by remote mo project tit

Please state the title of your graduation project (above) and the start date and end date (below). Keep the title compact and simple Do not use abbreviations. The remainder of this document allows you to define and clarify your graduation project.

start date 20 - 02 - 2023

20 - 07 - 2023

end date

#### INTRODUCTION \*\*

Please describe, the context of your project, and address the main stakeholders (interests) within this context in a concise yet complete manner. Who are involved, what do they value and how do they currently operate within the given context? What are the main opportunities and limitations you are currently aware of (cultural- and social norms, resources (time, money,...), technology, ...)

Pulmonary Fibrosis (PF) is a progressive, irreversible, and chronic lung disease that results in lung scarring and leads to a decline in lung function and increasing breathlessness. PF typi cally occurs in people over 45 years old, with an average age of 65 (Consultation Guide - EU-PF F, 2023). There is a wide range of causes and clinical manifestations of PF, and the most commo n one is Idiopathic Pulmonary Fibrosis (IPF). Moreover, diagnosing PF is an ongoing process tha t requires several examination methods and a multidisciplinary diagnosing team. Hence, delayed diagnosis and misdiagnosis commonly occur. The symptoms of PF develop over time, and individual differences exist in patients, while the most common ones are persistent coughing, shortness o f breath, and fatigue. Currently, there are two main treatment methods for PF: pharmacology (dr ug-based) treatment and non-pharmacology treatment, which includes lung transplantation, oxygen therapy, and pulmonary rehabilitation. As the disease is incurable and progresses differently with individual patients, it is necessary to monitor patients' disease courses continuously. He nce, the pulmonologists from Erasmus Medical Center developed the remote-monitoring tool (Figru e 1): IPF-online to support patients in measuring their lung functions at home and communicatin g with healthcare professionals without physical consultations. The aim of my graduation projec t is to enhance the current platform by investigating and integrating the patients' experience in everyday life, to optimize their health-related quality of life. Several stakeholder groups a re included and will be further investigated during my graduation project (Figure 2):1. Patient s themselves are the primary stakeholders since they are in charge of decision-making, keeping track of their disease course, and reorganizing their life to adapt to the changes brought by t he disease. 2. Patients' caregivers/families are also involved throughout the journey as they pr ovide care and support the patients. 3. Healthcare professionals are also significant stakeholde rs to be considered, including primary care providers (general practitioners) and secondary car e providers (hospitals), who take the roles in consultation, diagnosis, treatment, and shared d ecision-making processes. Apart from that, other healthcare professionals are involved in the t reatment process, including physiotherapists and dieticians. 4. The social environment surroundi ng the patients is also relevant, the most relevant are the peer patients and patient communiti es, which provides peer support and additional information and knowledge. Based on my findings f rom initial research by journey mapping, currently, there are several challenges that patients are facing during different stages of their care path which can negatively affect their healthrelated quality of life: 1. Patients experience difficulties in decision-making in different s tages of the disease, due to the lack of information and communication barriers with healthcare professionals. 2. The unexpectation of disease progression and acute exacerbation could cause patients anxiety and frustration. 3. Treatment plan is constantly adjusted corresponding to the disease progression, and patients need to spend extra time and energy to adapt to the new plan .4. Patients have to reorganize their daily life to adapt to the tremendous changes in every as pect, such as diet changes, sleeping difficulties, reduced mobilities, quitting jobs, and less social connection. In my graduation project, I want to actively engage in these challenges and i dentify their reasons, and develop potential solutions.

space available for images / figures on next page

IDE TU Delft - E8	SA Depa	rtment /// Gr	aduation project brief & study overview /// 2018-01 v30	Page 3 of
Initials & Name	R.	Zhang	Student number	4786629

Title of Project Optimizing pulmonary fibrosis patients experience by remote monitoring



## Personal Project Brief - IDE Master Graduation

## MOTIVATION AND PERSONAL AMBITIONS

Explain why you set up this project, what competences you want to prove and learn. For example: acquired competences from your MSc programme, the elective semester, extra-curricular activities (etc.) and point out the competences you have yet developed. Optionally, describe which personal learning ambitions you explicitly want to address in this project, on top of the learning objectives of the Graduation Project, such as: in depth knowledge a on specific subject, broadening your competences or experimenting with a specific tool and/or methodology, .... Stick to no more than five ambitions.

I am motivated to choose this project because it fits my interest in developing solutions for healthcare contexts involving diverse stakeholders and also helps me finish the medisign special ization. As I have yet to do any project related to data-enabled design, this project is also challenging for me to explore unfamiliar fields. Additionally, I have already done a research elective for the CardioLab in collaboration with Erasmus MC, therefore, I am already familiar with the context and have developed a great interest in further developing this project. I believe the results of this project will generate great value for the patients and the medical team. Competence I want to approve:— Ability to conduct context research and user experience research-Academic skills, including applying different research methodologies and delivering innovative research findings.— Ability to create meaningful and impactful user experience design—Ability to collaborate with a multidisciplinary teamCompetence I want to learn:— How to collect and process community data and use it as a tool to understand user experiences?— How to develop a data—enabled design in the healthcare context?— How to make my design align with ethical and medica l approval? e.g., how to deal with sensitive data and do research with vulnerable groups?— How to train myself and become a design researcher/PhD student in a healthcare-related field?

FINA		

In case your project brief needs final comments, please add any information you think is relevant.

IDE TU Delft - E&SA Department /// Graduation project brief & study overview /// 2018-01 v30

Page 7 of 7

Initials & Name R. Zhang

Student number 4786629

Title of Project Optimizing pulmonary fibrosis patients experience by remote monitoring

## **Tu**Delft

## Personal Project Brief - IDE Master Graduation

## PROBLEM DEFINITION \*\*

Limit and define the scope and solution space of your project to one that is manageable within one Master Graduation Project of 3 EC (= 20 full time weeks or 100 working days) and clearly indicate what issue(s) should be addressed in this project.

As a progressive and incurable disease, pulmonary fibrosis requires long-term management throug hout the patient's life. Moreover, the transition of healthcare context from hospital brings ch allenges to the patients, which impact different aspects of their daily lives. And this project will address PF patients' difficulties in managing their disease at home and communication wit h healthcare professionals. Though challenges are identified in different stages of patients' journey, the main scope of this project will be the patients' experiences after diagnosis and living with PF. There are two main research questions that need to be examined in my graduation project: 1. What are the patients' unmet needs during the after-diagnosis stage, meaning how and where patients miss information, skills, and feedback that are demanded to manage their dise ase effectively? 2. What kinds of data should be continuously collected from the patients to monitor patients' physical and mental experiences apart from the current measurements?

#### ASSIGNMENT\*

State in 2 or 3 sentences what you are going to research, design, create and / or generate, that will solve (part of) the issue(s) pointed out in "problem definition". Then illustrate this assignment by indicating what kind of solution you expect and / or aim to deliver, for instance: a product, a product-service combination, a strategy illustrated through product or product-service combination ideas, .... In case of a Specialisation and/or Annotation, make sure the assignment reflects this/these.

Design a patient-centered product-service system connecting PF patients and healthcare professio nals, which supports patients' self-monitoring activities and improves the communication between patients and doctors.

I expect to design a product-service system that enables PF patients to actively keep track of their physical and mental status related to their disease and treatment process in order to bet ter manage their diseases and reorganize their daily lives in a way that is not intrusive or overwhelming, but fits with their context and motivates them continuously use it. Secondly, I wil lesign the interaction of communicating the collected data effectively to both patients and doctors. Since PF patients and healthcare professionals are the target users of this PSS, hence, both of their experiences will be incorporated into the development of effective and relevant solutions for both.

IDE TU Delft - E&SA Department /// Graduation project brief & study overview /// 2018-01 v30

Page 5 of 7

Initials & Name R. Zhang

Student number 4786629

Title of Project Optimizing pulmonary fibrosis patients experience by remote monitoring

# **TU**Delft

## Personal Project Brief - IDE Master Graduation

## PLANNING AND APPROACH \*\*

Include a Gantt Chart (replace the example below - more examples can be found in Manual 2) that shows the different phases of your project, deliverables you have in mind, meetings, and how you plan to spend your time. Please note that all activities should fit within the given net time of 30 EC = 20 full time weeks or 100 working days, and your planning should include a kick-off meeting, mid-term meeting, green light meeting and graduation ceremony. Illustrate your Gantt Chart by, for instance, explaining your approach, and please indicate periods of part-time activities and/or periods of not spending time on your graduation project, if any, for instance because of holidays or parallel activities.

start date 20 - 2 - 2023 20 - 7 - 2023 end date



The project is planned for 100 days (20 project weeks). It's necessary to apply for ethical approval (HEEC) and medical approval (METC) to conduct co-creation sessions, interviews, and user tests with patients. Although a realistic waiting time has already been taken into account, the planning of co-creation sessions and user tests may change due to the waiting time for approva 1. The detailed planning of co-creations and user tests will be updated once the ethical and m edical approvals are received and patients are recruited.

IDE TU Delft - E&SA Department /// Graduation project brief & study overview /// 2018-01 v30 Page 6 of 7 Initials & Name R. Zhang Student number 4786629 Title of Project Optimizing pulmonary fibrosis patients experience by remote monitoring

# **Appendix B: HREC approval letter**

Date 11-Apr-2023

Contact person Dr. Cath Cotton, Policy Advisor

Academic Integrity
E-mail c.m.cotton@tudelft.nl



Human Research Ethics Committee TU Delft (http://hrec.tudelft.nl)

Visiting address
Jaffalaan 5 (building 31)
2628 BX Delft

Postal address
P.O. Box 5015 2600 GA Delft
The Netherlands

Faculty of Technology, Policy and Management

Dr. Ir. U. Pesch

Chair HREC

Ethics Approval Application: Improving pulmonary fibrosis patient remote monitoring systems through Community Journey Mapping to increase HRQoL(health-related quality of life) and patient empowerment Applicant: Zhang, Ruixuan

Dear Ruixuan Zhang,

It is a pleasure to inform you that your application mentioned above has been approved.

In addition to any specific conditions or notes, the HREC provides the following standard advice to all applicants:

- In light of recent tax changes, we advise that you confirm any proposed remuneration of research subjects with your faculty contract manager before going ahead.
- Please make sure when you carry out your research that you confirm contemporary covid protocols
  with your faculty HSE advisor, and that ongoing covid risks and precautions are flagged in the informed
  consent with particular attention to this where there are physically vulnerable (eg: elderly or with
  underlying conditions) participants involved.
- Our default advice is not to publish transcripts or transcript summaries, but to retain these privately for specific purposes/checking; and if they are to be made public then only if fully anonymised and the transcript/summary itself approved by participants for specific purpose.
- Where there are collaborating (including funding) partners, appropriate formal agreements including clarity on responsibilities, including data ownership, responsibilities and access, should be in place and that relevant aspects of such agreements (such as access to raw or other data) are clear in the Informed Consent.

Good luck with your research!

Sincerely.

# **Appendix C: Topic modelling results**

Cluster	Meaning	Percentage positve/negative	Total posts
topic 0	Supplement treatment method: Oxygen therapy: usage of oxygen concentrators	0.526189524	5414
topic 1	lung transplant surgery: decision making, after- care	0.761532447	4240
topic 2	medication: usage of non-traditional medicine (metformin, ,thalidomide)	0.587243402	2671
topic3	loss of loved ones, support and sympathy from peer group	0.663209274	1837
topic 4	Symptoms: Coping strategies against coughing: medication, cough syrup, supplements, physical exercises	0.588688946	1250
topic 5	medication: experiences of taking esbriet: usage, effects and side effects	0.369030391	1199
topic 6	medication: experiences of taking ofev: usage, effects and side effects	0.442546584	1127
topic 7	Decision-making: choosing health insurances to covertreatment expenses	0.51826484	1037
topic 8	Diagnosis: Examination - Biopsy: what do patient need to prepare for it? Uncertainty of the experience of biopsy; difficulties in decision-making; Fear of the	0.373931624	916
topic 9	Environmentalfactors: Climatic condition influences on patients'syptoms: temperature, air quality, humidity	0.492727273	850
topic 10	Decision-making: choosing clinic and doctors	0.826086957	837
topic 11	Change in lifestyle: diet change, loss of appetite and losing weight Prepare for transplants surgery: maintain BMI	0.539784946	808
topic 12	Medication: prednisone: dosage of use, strong side effects	0.315914489	744
topic 13	Supplement treatment method: CBD	0.492877493	706
topic 14	Symptoms: Anti-reflux: medication (omerprazole), keep strict diet, sleep on the bed with angle	0.394805195	704
topic 15	Scam treatment method: stem cell therapy	0.352549889	599

topic 16	Hypersensitivity pneumonitis: different sources of allergen (One of the subgroups of interstitial lung disease is those that are related to	0.240310078	698
topic 17	Causes: Amiodarone-induced pulmonary fibrosis	0.322033898	685
topic 18	Supplementtreatment method: Enzyme supplements	0.634782609	683
topic 19	Coping strategies against coughing - saline; naral spray against dry nose	0.492997199	616
topic 20	Indicator of disease progression: diffuse capacity for carbon monoxide and forced vital capacity		614
topic 21	Symptoms: cramps, chest pain For female patients: bras adds extra irritation	0.171232877	598
topic 22	Medication: antioxident - NAC (N-acetylcysteine) is an antioxidantthat may help to prevent lung damage in people with idiopathic pulmonary fibrosis;	0.615969582	545
topic 23	Medication: dosage, usage and side effects of taking all kinds of medication		537
topic 24	Cheering-up and encouragement from peers	0.988235294	535
topic 25	End-of-life: hospice care; palliative care (providing relieffrom symptoms, optimizing QoL); patients have postitive attitute towards it	0.613180516	524
topic 26	Vaccinations are effective tools to prevent infections in pulmonary fibrosis patients, to help stay healthy	0.394736842	492
topic 27	Compassionate allowance from government: Supplemental Security Income (US)	0.377118644	470
topic 28	pulmonary fibrosis	0.370731707	443
topic 29	Oxygensaturation: Is it helpful to trace the percentage? Individual differences on patients experiences; Doubts and communication gap with	0.34375	434
topic 30	Breathing exercise, Physical exercises are experienced as benefical imroving symptoms; Pulmonary rehabilitatation is perceived as challenging but also helpful.	0.823321555	430
topic 31	Emotion: loneliness, sympathy towards others, fear of the disease when newly diagnoses	0.640243902	412
topic 32	Educating new users & difficulties of finding the needed information	0.565853659	392

# **Appendix C: Topic modelling results**

topic 33	Community support: offline support group, attending webinars, lack of support and attention from national fund	0.866336634	380
topic 34	Emotion: thankful towards peers	0.994382022	362
topic 35	Causes: usage of 'agent orange' (chemical herbicide used in US military)	0.33333333	351
topic 36	Usage of oxygen device: Emotions: frustration of the fact of using oxygen tank; shame and embrassment of using it in public; Tabu of using oxygen	0.35828877	345
topic 37	Recommendation on doctors and clinics	0.795454545	340
topic 38	Usage of oximeter: choosing the right device	0.653179191	335
topic 39	celebrating	0.961538462	328
topic 40	IPF as an interstitial lung disease	0.270588235	319
topic 41	Best wishes, prayers, congratulations on good news	0.974025974	318
topic 42	Making connections with peers: send friend request	0.859375	310
topic 43	Causes: rheumatoid arthritis (RA) caused complication of PF	0.322033898	273
topic 44	Purchase, pharmacy, online store	0.79389313	268
topic 45	Causes: familial pulmonary fibrosis, tests and doubts towards it	0.205128205	256
topic 46	Oxygen: differences between day and night; difficulties in sleeping at night, sleep apnea; Coping strategies: overnight oximetry, sleep study	0.50877193	251
topic 47	Side effect of medication: sensitive to sun, rashes Coping strategies: wearing sun screen, stay away from beach	0.28057554	244
topic 48	Purchase medication, from pharmacy, amazon	0.477272727	243
topic 49	Attractions: DIY activities, trips	0.981395349	239

topic 50	Medication: cellcept	0.486956522	234
topic 51	loss of loved ones, grieving	0.468085106	225
topic 52	Diagnosis: misdiagnosis, unsatisfied with the doctor,	0.296	224
	switching to other doctors and clinics		
topic 53	Medication: strong side effects of taking statins	0.214285714	222
topic 54	Medication: antibiotic medicines (doxycycline)	0.342342342	220
	, , , , , , , , , , , , , , , , , , , ,		
topic 55	url	0.827586207	219
topic 56	Medication: thrush caused by side effects of	0.352941176	219
	medication		
topic 57	Changing in life style: becoming sensitive to scents	0.217687075	218
	such as artificial fragrances; Doubt of hyrogen peroxide as a treatment method?		
topic 58	url	0.8	214
topic 59	Changing in life style: singing or participating in choirs is difficult, but it brings people joy and calming;	0.546511628	214
	positive attitude		
topic 60	people not shows up anymore	0.722627737	210
	1 and	1	210
topic 61	Appreciation	1	210
topic 62	Humor, jokes	0.914893617	204
topic 63	Changing in life style: taking shower with oxygen	0.534653465	204
topic us	device is difficult; Coping strategy: using cannula and	0.334033403	
	long oxygen tubes in the shower		
topic 64	Changing in life style: give up on keeping	0.627906977	200
	pets/plants; unwillingness to be part with their pets		
topic 65	Changing in life style: daily mobility, using	0.77777778	199
	wheelchairs and mobility scooters		I
topic 66	Medication: pirfenidone; discussion on whether it's	0.423913043	189
	effective		

# **Appendix C: Topic modelling results**

topic 66	Medication: pirfenidone; discussion on whether it's effective	0.423913043	189
topic 67	Influence of smoking: quit smoking after diagnosed; Causes: Asbestosis is a type of pulmonary fibrosis, or lung scarring, specifically caused by inhaling		188
topic 68	Rehabilitation center, webnars	0.875	184
topic 69	Medication: morphine (reduce pain), used in final stage of the disease or hospice; Positive attitude towards it: reduce a lot pain, brings comfort	0.5625	175
topic 70	Raising awareness and advocacy about PF	0.554347826	164
topic 71	Changing in lifstyle: difficulties in sleeping; Coping strategy: wedge pillow, adjustable bed to help improve sleep	0.769230769	163
topic 72	Symptoms: clubbing fingers; (The tips of the fingers enlarge and the nails become extremely curved from frontto back. Clubbed fingers is a symptom of	0.206185567	162
topic 73	Treatment: laser therapy; controversial method evokes debates	0.392857143	158
topic 74	Nonspecific Interstitial Pneumonitis (NSIP)	0.571428571	158
topic 75	Changing in lifstyle: hair loss due to unclear causes, possiblely due to side effects of medication. Blue streak challenge to support PF research	0.488636364	155
topic 76	Diagnosis: syptoms of lung scarring, doubting if it's PF, looking for medical advices online; misdiagnosis	0.294736842	148
topic 77	Aftertransplant surgery: fear of organ rejection aftersurgery; high cost of anti-rejection medicines, lack of information about the cost and wether	0.434782609	132
topic 78	Diagnosis: hard to accept the truth; unexpectation of disease progression	0.511627907	130
topic 79	Causes: scleroderma related PF; Doubts and confuses about lung transplat for these patients	0.441176471	130
topic 80	Amen	0.88034188	129
topic 81	Fatigue due to side effect of medication;	0.285714286	129
topic 82	Sorry	0.481481481	127

topic 83	Vitamin supplement: positive attitude towards it	0.526315789	125
topic 84	Appreciation	1	122
topic 85	Emotion: anxiety, depression, panic attack; Unclear cause, probably due to side effects of medication. Coping strategies: anti-anxiety/depression	0.421052632	121
topic 86	Welcome	0.97826087	119
topic 87	Influence of COVID-19: fear of contacting with people; reduced opportunies of going out, meeting families and friends	0.14516129	117
topic 88	Appreciation	1	116
topic 89	Diary of husband's disease progression	0.851851852	115
topic 90	Prayers for surgery	0.846153846	114
topic 91	Changing in lifestyle / Decision-making: continue or stop working Continue working: challenging but meaningful,	0.565217391	113
topic 92	Self-protection: wearing face masks to prevent flu, allergens and COVD-19	0.62295082	113
topic 93	Medication: Esbriet (pirfenidone): dosage and usage, individual differences	0.5	110
topic 94	Changing in lifestyle: wearing glassess is inconvenient and uncomfortable; Coping strategy: special glasses designed for people who need	0.80952381	107
topic 95	Medication: Esbriet (pirfenidone): strong side effects, decided to stop taking it	0.434782609	107
topic 96	Appreciation	0.950980392	105
topic 97	Appreciation	1	105
topic 98	Grieving for others' loss	0.4	103
topic 99	Waiting list for lung tranplant surgery	0.828947368	103

# Appendix D: Final re-interpreted categories and topics

	5+66+93 6+23 50 12 22 53 54 56	Topic usage of non-traditional medicine (metformin, thalidomide) experiences of taking esbriet (pirfenidone): usage, effects and side effects; discuss whether it is effective; individual differences; decide to stop using it experiences of taking ofev: usage, effects and side effects cellcept (to prevent reject following organ tranplant surgery) prednisone: dosage of use, strong side effects antioxidant - NAC (N-acetylcysteine) is an antioxidant that may help to prevent lung damage in people with idiopathic pulmonary fibrosis; Supplement: curcumin supplement	2671 1498 1664 234 744	
Experience on pharmological	5+66+93 6+23 50 12 22 53 54	thalidomide) experiences of taking esbriet (pirfenidone): usage, effects and side effects; discuss whether it is effective; individual differences; decide to stop using it experiences of taking ofev: usage, effects and side effects cellcept (to prevent reject following organ tranplant surgery) prednisone: dosage of use, strong side effects antioxident - NAC (N-acetylcysteine) is an antioxidant that may help to prevent lung damage in people with idiopathic pulmonary	1498 1664 234	
Experience on pharmological	6+23 50 12 22 23 53 54	experiences of taking esbriet (pirfenidone): usage, effects and side effects; discuss whether it is effective; individual differences; decide to stop using it experiences of taking ofev: usage, effects and side effects cellcept (to prevent reject following organ tranplant surgery) prednisone: dosage of use, strong side effects antioxident - NAC (N-acetylcysteine) is an antioxidant that may help to prevent lung damage in people with idiopathic pulmonary	1664 234	
Experience on pharmological	6+23 50 12 22 23 53 54	is effective; individual differences; decide to stop using it experiences of taking ofev: usage, effects and side effects cellcept (to prevent reject following organ tranplant surgery) prednisone: dosage of use, strong side effects antioxident - NAC (N-acetylcysteine) is an antioxidant that may help to prevent lung damage in people with idiopathic pulmonary	1664 234	
Experience on pharmological	6+23 50 12 22 23 53 54	using it experiences of taking ofev: usage, effects and side effects cellcept (to prevent reject following organ tranplant surgery) prednisone: dosage of use, strong side effects antioxident - NAC (N-acetylcysteine) is an antioxidant that may help to prevent lung damage in people with idiopathic pulmonary	1664 234	
pharmological	50 12 22 53 54	experiences of taking ofev: usage, effects and side effects cellcept (to prevent reject following organ tranplant surgery) prednisone: dosage of use, strong side effects antioxident - NAC (N-acetylcysteine) is an antioxidant that may help to prevent lung damage in people with idiopathic pulmonary	1664 234	
pharmological	50 12 22 53 54	side effects cellcept (to prevent reject following organ tranplant surgery) prednisone: dosage of use, strong side effects antioxident - NAC (N-acetylcysteine) is an antioxidant that may help to prevent lung damage in people with idiopathic pulmonary	234	
pharmological	50 12 22 53 54	cellcept (to prevent reject following organ tranplant surgery) prednisone: dosage of use, strong side effects antioxident - NAC (N-acetylcysteine) is an antioxidant that may help to prevent lung damage in people with idiopathic pulmonary	234	
pharmological	12 22 53 54	tranplant surgery) prednisone: dosage of use, strong side effects antioxident - NAC (N-acetylcysteine) is an antioxidant that may help to prevent lung damage in people with idiopathic pulmonary		
pharmological	12 22 53 54	prednisone: dosage of use, strong side effects antioxident - NAC (N-acetylcysteine) is an antioxidant that may help to prevent lung damage in people with idiopathic pulmonary		
pharmological	22 53 54	antioxident - NAC (N-acetylcysteine) is an antioxidant that may help to prevent lung damage in people with idiopathic pulmonary	744	
treatment (10)	53 54	antioxidant that may help to prevent lung damage in people with idiopathic pulmonary		
	53 54	damage in people with idiopathic pulmonary		
	54			
	54	ribrosis, <b>supplement:</b> curcumin supplement	545	
	54	strong side effects of taking statins	222	
		antibiotic medicines (doxycycline)	222	
	20	thrush caused by side effects of medication	220	
	30	morphine (reduce pain), used in final stage of the	219	
	69	disease or hospice; Positive attitude towards it:		
	03	reduce a lot pain, brings comfort	175	
	Total	. cases a for party orings conflict	8192	
		Doubts towards oxygen therapy: usage of oxygen	- 0132	20.50%
	0	concentrators	5414	
	13	CBD oil	706	
	83	Vitamin supplements	125	
	18	Enzyme supplements	683	
	15	Scam treatment method: stem cell therapy	699	
	73	laser therapy; controversial method evokes		
	/5	debates	158	
		Breathing exercise, Physical exercises are		
	30+68	experienced as benefical imroving symptoms;		
Experience on non-	30100	Pulmonary rehabilitatation is perceived as		
pharmological		challenging but also helpful	614	
treatments (11)	56	thrush caused by side effects of medication	219	
		Usage of oxygen device: frustration of the fact of		
	36	using oxygen tank; shame and embrassment of	245	
		using it in public; Tabu of using oxygen	345	
	26	Vaccinations are effective tools to prevent		
	26	infections in pulmonary fibrosis patients, to help	492	
		stay healthy palliative care (providing relief from symptoms,	492	
	25	optimizing QoL); patients have postitive attitute		
	23	towards it	524	
	Total	towards it	9979	
		coughing & coping strategies		250%
	4+19			
			1866	
		stomach-reflux		
	14			
	14			
Experience around			704	
symptoms (5)	21	cramps, chest pain; For female patients: bras	598	
		adds extra irritation		
	70	clubbing fingers; (The tips of the fingers enlarge		
	72	and the nails become extremely curved from		
		front to back	162	
	28	arterial hypertension caused by pulmonary	443	
	Total	fibrosis	3773	

	1	wether to take lung transplant surgens	4240	
	1	wether to take lung transplant surgery	4240	
	7	choosing health insurances to cover treatment		
		expenses	1037	
	38	Choose the oximeter to have correct reading	335	
		decide to stop taking medication that cause		
Experience around	95	strong side effect and choose quality of life	107	
decision-making	67	decide to quit smoking after diagnosis	188	
moments (8)		continue or stop working: Continue working:	200	
		challenging but meaningful, dignity of life;		
	91	Stop working: disability, huge change to life, hard		
		to balance between working and visit doctors &		
		tests	113	
	10	Look for second opinion when unsatisfied with		
	10	diagnosis	837	
		take biopsy examination: Uncertainty of the		
	8	experience of biopsy; difficulties in decision-		
		making; Fear of the sides effects of biopsy	916	
		making, real of the sides effects of biopsy		
			7773	
	52	misdiagnosis, unsatisfied with the doctor		switching to other
				doctors and hospitals
	31	fear of the disease when newly diagnoses	412	
		syptoms of lung scarring, doubting if it's PF,		
	76	looking for information online; misdiagnosis	148	
		Indicator of disease progression: diffuse		
Experience around	20	capacity for carbon monoxide and forced vital		
their diagnosis (6)	20		C14	
		capacity	614	
		Oxygen saturation: Is tracing the percentage		
	29	helpful? Individual differences on patients		
		experiences; Doubts and communication gap		
		with doctors	434	
	78	uncertain about the diagnosis results	130	
	Total	and the magnetic field the magnetic feet and	1962	
	70141	Hypersensitivity pneumonitis: different sources	1302	3.40/0
		of allergen		
	16	(One of the subgroups of interstitial lung disease		
		is those that are related to environmental		
		exposures, referred to as "hypersensitivity		
		pneumonitis.)	698	
	17	Amiodarone-induced pulmonary fibrosis	685	
Describing around		usage of 'agent orange' (chemical herbicide used		
-	35	in US military)		
causes (7)			251	
		,,	351	
	40	Unclear causes:IPF	351 319	
		Unclear causes:IPF Causes: familial pulmonary fibrosis, tests and	319	
	40 45	Unclear causes:IPF		
	45	Unclear causes:IPF Causes: familial pulmonary fibrosis, tests and	319	
		Unclear causes: IPF Causes: familial pulmonary fibrosis, tests and doubts towards it	319	
	45 43	Unclear causes: IPF Causes: familial pulmonary fibrosis, tests and doubts towards it rheumatoid arthritis (RA) caused complication of PF	319 256	
	45	Unclear causes: IPF Causes: familial pulmonary fibrosis, tests and doubts towards it freumatoid arthritis (RA) caused complication of PF scleroderma related PF; Doubts and confuses	319 256 273	
	45 43 79	Unclear causes: IPF Causes: familial pulmonary fibrosis, tests and doubts towards it rheumatoid arthritis (RA) caused complication of PF	319 256 273 130	
	45 43	Unclear causes: IPF Causes: familial pulmonary fibrosis, tests and doubts towards it rheumatoid arthritis (RA) caused complication of PF scleroderma related PF; Doubts and confuses about lung transplat for these patients	319 256 273	
	45 43 79 Total	Unclear causes: IPF Causes: familial pulmonary fibrosis, tests and doubts towards it rheumatoid arthritis (RA) caused complication of PF scleroderma related PF; Doubts and confuses about lung transplat for these patients	319 256 273 130	
	45 43 79	Unclear causes: IPF Causes: familial pulmonary fibrosis, tests and doubts towards it rheumatoid arthritis (RA) caused complication of PF scleroderma related PF; Doubts and confuses about lung transplat for these patients  becoming sensitive to scents such as artificial fragrances; Doubt of hyrogen peroxide as a	319 256 273 130 2712	6.00%
	45 43 79 Total	Unclear causes:IPF Causes: familial pulmonary fibrosis, tests and doubts towards it  rheumatoid arthritis (RA) caused complication of PF  scleroderma related PF; Doubts and confuses about lung transplat for these patients  becoming sensitive to scents such as artificial  fragrances; Doubt of hyrogen peroxide as a  treatment method?	319 256 273 130	6.00%
	45 43 79 Total 57	Unclear causes: IPF Causes: familial pulmonary fibrosis, tests and doubts towards it rheumatoid arthritis (RA) caused complication of PF scleroderma related PF; Doubts and confuses about lung transplat for these patients  becoming sensitive to scents such as artificial fragrances; Doubt of hyrogen peroxide as a	319 256 273 130 2712	6.00%
	45 43 79 Total	Unclear causes:IPF Causes: familial pulmonary fibrosis, tests and doubts towards it  rheumatoid arthritis (RA) caused complication of PF  scleroderma related PF; Doubts and confuses about lung transplat for these patients  becoming sensitive to scents such as artificial  fragrances; Doubt of hyrogen peroxide as a  treatment method?	319 256 273 130 2712	6.00%
	45 43 79 Total 57	Unclear causes: IPF Causes: familial pulmonary fibrosis, tests and doubts towards it rheumatoid arthritis (RA) caused complication of PF scleroderma related PF; Doubts and confuses about lung transplat for these patients  becoming sensitive to scents such as artificial fragrances; Doubt of hyrogen peroxide as a treatment method? singing or participating in choirs is difficult, but it brings people joy and calming; positive attitude	319 256 273 130 2712	6.00%
	45 43 79 Total 57	Unclear causes: IPF Causes: familial pulmonary fibrosis, tests and doubts towards it rheumatoid arthritis (RA) caused complication of PF scleroderma related PF; Doubts and confuses about lung transplat for these patients  becoming sensitive to scents such as artificial fragrances; Doubt of hyrogen peroxide as a treatment method? singing or participating in choirs is difficult, but it brings people joy and calming; positive attitude taking shower with oxygen device is difficult;	319 256 273 130 2712	6.00%
	45 43 79 Total 57	Unclear causes: IPF Causes: familial pulmonary fibrosis, tests and doubts towards it rheumatoid arthritis (RA) caused complication of PF scleroderma related PF; Doubts and confuses about lung transplat for these patients  becoming sensitive to scents such as artificial fragrances; Doubt of hyrogen peroxide as a treatment method? singing or participating in choirs is difficult, but it brings people joy and calming; positive attitude taking shower with oxygen device is difficult; Coping strategy: using cannula and long oxygen	319 256 273 130 2712 218	6.00%
	45 43 79 Total 57	Unclear causes:IPF Causes: familial pulmonary fibrosis, tests and doubts towards it rheumatoid arthritis (RA) caused complication of PF scleroderma related PF; Doubts and confuses about lung transplat for these patients  becoming sensitive to scents such as artificial fragrances; Doubt of hyrogen peroxide as a treatment method? singing or participating in choirs is difficult, but it brings people joy and calming; positive attitude taking shower with oxygen device is difficult; Coping strategy: using cannula and long oxygen tubes in the shower	319 256 273 130 2712	6.00%
	45 43 79 Total 57 59	Unclear causes: IPF Causes: familial pulmonary fibrosis, tests and doubts towards it rheumatoid arthritis (RA) caused complication of PF scleroderma related PF; Doubts and confuses about lung transplat for these patients  becoming sensitive to scents such as artificial fragrances; Doubt of hyrogen peroxide as a treatment method? singing or participating in choirs is difficult, but it brings people joy and calming; positive attitude taking shower with oxygen device is difficult; Coping strategy: using cannula and long oxygen tubes in the shower give up on keeping pets/plants; unwillingness to	319 256 273 130 2712 218 214	6.00%
	45 43 79 Total 57	Unclear causes:IPF Causes: familial pulmonary fibrosis, tests and doubts towards it rheumatoid arthritis (RA) caused complication of PF scleroderma related PF; Doubts and confuses about lung transplat for these patients  becoming sensitive to scents such as artificial fragrances; Doubt of hyrogen peroxide as a treatment method? singing or participating in choirs is difficult, but it brings people joy and calming; positive attitude taking shower with oxygen device is difficult; Coping strategy: using cannula and long oxygen tubes in the shower	319 256 273 130 2712 218	6.00%
	45 43 79 Total 57 59 63 64	Unclear causes: IPF Causes: familial pulmonary fibrosis, tests and doubts towards it rheumatoid arthritis (RA) caused complication of PF scleroderma related PF; Doubts and confuses about lung transplat for these patients  becoming sensitive to scents such as artificial fragrances; Doubt of hyrogen peroxide as a treatment method? singing or participating in choirs is difficult, but it brings people joy and calming; positive attitude taking shower with oxygen device is difficult; Coping strategy: using cannula and long oxygen tubes in the shower give up on keeping pets/plants; unwillingness to	319 256 273 130 2712 218 214	6.00%
	45 43 79 Total 57 59	Unclear causes: IPF Causes: familial pulmonary fibrosis, tests and doubts towards it rheumatoid arthritis (RA) caused complication of PF scleroderma related PF; Doubts and confuses about lung transplat for these patients  becoming sensitive to scents such as artificial fragrances; Doubt of hyrogen peroxide as a treatment method? singing or participating in choirs is difficult, but it brings people joy and calming; positive attitude taking shower with oxygen device is difficult; Coping strategy: using cannula and long oxygen tubes in the shower give up on keeping pets/plants; unwillingness to be part with their pets	319 256 273 130 2712 218 214	6.00%
	45 43 79 Total 57 59 63 64	Unclear causes: IPF Causes: familial pulmonary fibrosis, tests and doubts towards it rheumatoid arthritis (RA) caused complication of PF scleroderma related PF; Doubts and confuses about lung transplat for these patients  becoming sensitive to scents such as artificial fragrances; Doubt of hyrogen peroxide as a treatment method? singing or participating in choirs is difficult, but it brings people joy and calming; positive attitude taking shower with oxygen device is difficult; Coping strategy: using cannula and long oxygen tubes in the shower give up on keeping pets/plants; unwillingness to be part with their pets daily mobility, using wheelchairs and mobility	319 256 273 130 2712 218 214 204	6.00%

# Appendix D: Final re-interpreted categories and topics

	Total		4567	11.709
	85	anxiety, depression, panic attack; Unclear cause, probably due to side effects of medication.	121	
	87 +92	Influence of COVID-19: fear of contacting with people; reduced opportunies of going out, meeting families and friends	230	
	9	Climatic condition influences on patients' syptoms: temperature, air quality, humidity	850	
	49	DIY activities, trips	239	
	94	wearing glassess is inconvenient and uncomfortable when using oxygen tank	107	
	11	diet change, loss of appetite and losing weight  Prepare for transplants surgery: maintain BMI (weight) in the required range	808	
changes in ne(10)	47	Side effect of medication: sensitive to sun, rashes Coping strategies: wearing sun screen, stay away from beach	244	
adapt to the changes in Ife(16)	75	hair loss due to unclear causes, possiblely due to side effects of medication.	155	
djusting lifestyle to	81	Fatigue influencing daily activities	129	
	46+71	difficulties in sleeping;	414	

# Appendix E: HPs Co-creation session set up

# 1<sup>st</sup> co-creation with healthcare professionals session work plan

Time: 1.5 hour Location: Erasmus MC

Participants: pulmonologists (3), specialist nurse (1), designers (2), computer scientists (2)

#### Research Questions:

- To scope down the focus: what are the most important challenges that need to be addressed in doctors' perspective to improve HRQOL of patients?
- What factors are important to optimize for using explainable AI in the context of the medical domain?
- 3. What kinds of information need to be collected from the patients to help the doctors gain context in these challenges?

The 8 diverse participants in the session with expertise in patient care, design and explainable Al will result in an expert group that is able to validate and generate insights at the intersection of all these research fields.

Time	Activity	Goal	Tasks for participants	Modality
20	Introduction	Share the research methods, limitations (US context), provide schedule for the remainder of the session.	Waiting for everyone to settle down & Quick introduction Jiwon(5min)  Give quick presentation about project (10min)  Look through and sign the informed consent form (5 min)	PowerPointl C form
15	Validate Journey map (Group)	Help participants to understand the timeline and to validate the Journey map.	1. The participants will first use markers to draw on the main line with their thoughts on the patient journey. (10min) 2. Discuss the changes, what was inspiring? What went wrong? How it is different between Dutch & US context (5min)	Booklet
15	Identify the most	Find the challenges that are most important to improve	Each participant fills in the first page in the booklet.	Map, Cards & Booklet

	important	on.		
	challenges		Look through the patient topic	
	(Group)		cards. And each participant	
			picks 2 topic cards that they	
			think is the most important to	
			ask during their consultation	
			with patients; And put them in	
			the Hospital-home spectrum	
			(10min)	
			(10min)	
			Discuss about the choices.	
			(5min)	
5		Do they understand, trust	Explain how the protype system	Prototype
		the explainability generated	works to the participants using	&Booklet
		by the system and is it useful.	the tutorial page at the start of	
		Find implicit requirements by	the system	
		using the prototype.	Tutorial shows:	
			an example persona -> posts	
			generated by the persona-> AI	
			processing -> doctor interface.	
			The booklet shows:	
			How a persona would look like	
			Explain the assignment that	
			they must perform in the	
			PowerPoint	
			(5min)	
			Show how to use the system on	
			the screen	
			Each participant gets a separate	
			laptop to use, look through the	
			3 example patients that were	
			pre-made by us to display the	
			different functions of the	
			system.	
			The participants will use the	
			system to read the	
			main/sub-categories and	
			sentiment generated from the	
			problem posts the pre-made	
			patients are experiencing. They	
			parama are experiencing. They	

5	Closing	Close the session and thank the participants	and how those would look like. (20min)	Cookies
			information presented and if they used and trusted the explainability hints and if they think they needed more hints	
			will hold a structured discussion on if they understood the	
			we based the messages on. We	
			see if they match the ones that	
			what personas they created and	
			From these results we ask them	
			(10min)	
			clicking on the hint button.	
			explainability for doing this by	
			pre-made patients they explore in the system. They can use the	
			personas that match the 3	
			must create in their booklet 3	


# **Appendix F: HPs Co-creation booklet**






# Co-creation session booklet 7th of March


Healthcare professionals co-creation session for designing for Pulmonary Fibrosis patients



Your experience with AI
Step 1: Think about your past experience, do you have experience with Articial Intelligence technologies?  Step 2: How AI can help you as a healthcare professionals?  Step 3: How do you feel towards AI? Please fill in the scale questions in the bottom.
Step 1: My experience with Al: Step 2: I want to know about Al:
Step 3:  Al should be used in healthcare domain
Strongly disagree Neutral Strongly agree
I have a strong understanding of AI



# **Appendix E: HPs Co-creation booklet**




# Thank you for your participation!

Your insights are valuable for us to design for PF patients.
This booklet will be picked up by me in the end of this session.

Ruixuan Zhang


# Appendix H: Results brainstorming session with designers

**Understanding and management of medication** 



# Appendix H: Results brainstorming session with designers

**Understanding Treatment and medication options** 




# Appendix H: Results brainstorming session with designers

Lifestyle adjusting to adapt to changes in life











# Appendix H: Results brainstormina session with designers

Understanding and management of oxygen therapy



# Appendix H: Results brainstormina session with designers

Symptom monitoring and management



# Appendix I: Patient validation session set up & questionnaire

## 1. Introduction [5min]

## [Welcome & Explain the project]:

Hi, we're Ruixuan and Rembrandt, and we are researchers from EMC] This interview is about a research project investigating PF patient disease management at home, and we aim to facilitate your disease management and improve the quality of life.

And that's why we designed a new home-monitoring system (a smartphone APP), and we have your feedback by using it, and it would be extremely valuable for us to hear your opinions.

## [Recording & Consent form]:

The interview will be audio-recorded, And during the interview, would you allow us to take some pictures of you using the product (without having your face on it), and it will only be used internally within our project team to analyze the test results, not for any other purposes.

You can sign the consent form here! [Read the IC form to patients if he has difficulties reading it]

#### [Test procedure]:

The whole interview will take around 45min, and the structure of the tests has roughly 2 parts:

- we will start with some general questions;
- Then you will get some small tasks that you can perform in the app, and we will ask several questions after each task.

## 2. Pre-test interview [5min]

- Can you tell me about your experience with technology, such as smartphones, tablets, or computers? Are you comfortable using them?
- Have you heard of or used the IPF-Online app? If so, how do you feel about it?
- Are there any specific challenges or concerns you have when it comes to using technology or smart devices and healthcare APPs?
- Have you heard of chatbot or voice assistant, like Siri or Amazon Alexa?

## 3. Testing tasks [30min]

There are 2 small tasks in this test, and it is important to note that we are not testing the actual app but a prototype: a first version that represents the new design as well as possible, which means that not all functionalities are fully working. So don't worry if something may not work as expected! We are testing the prototype, not your skills in the use of it.

And there are no right or wrong comments! Any feedback is helpful for our process, so don't hesitate on what you want to say.

Now let's start the test! I will give you some scenario in disease management which may not applicable for you case, but you can imagine the situation while doing the tasks.

## TASK 1: Navigate to 'my progress' and check the health summary [5min]

[If the patient said he hasn't used the IPF-online before, explain how the spirometer works to him] "You have constantly been doing the self-lung-function tests in the past month, and today you want to view your status and progress, could you check the overview of your lung function in the App?"

[If he can't find it, helps him find it and continue with the test]

# TASK 2: Nevigate to eConsult and ask a question about the measurements [15min]

"Great! Now you see an overview of your lung function measurements in the past month [Exlain that we're just simulating it not using his real data]. And let's take a look at it, how do you think of this overview? (does he understand what it means)

"Well, the Al also noticed that your lung function was fluctuating in the first half of May and in some days there are declines, while in the second half, it was quite stable. **What reason do you think causes the fluctuation?**"

[After patient answers] We can also try to find the reason by consulting the virtual assistant! You can now try to find the eConsult and ask about your concerns.

[Rae do the observation and see how the patient interact with chatbot]

[When Rae gives a hint that the participants already tried all the interactions with chatbot, Rembrandt can cut in and ask follow-up questions:]

- (1) About reliability:
  - What do you think of the accuracy and reliability of the information provided by the chathot?
  - Did you feel that the answers provided by the chatbot were consistent with your practice or what you have learned from other reliable sources?
- (2) Explainability:
  - Did you use the further explanation function when talking with the chatbot?
  - Did the chatbot effectively explain the information and answers it provided to your questions?
  - Did the explanation help you to understand the answers provided by the chatbot?
- (3) Trustworthy:
  - Did you find the information provided by the chatbot to be trustworthy and credible?
  - What factors or features contributed to your perception of the chatbot as a trustworthy source of information?

5 min break for the patient, Rae & Rembrandt discuss next step

# Appendix I: Patient validation session set up & questionnaire

## TASK 3: Testing resource function

[If the patient is tired or time exceeds this part can leave out]

"Now let's go to the last task. Imagine you would like to stay informed about the latest news and developments in PF research. Try to use the resource function to browse through interesting news or summaries of articles."

## [After patient completes it, ask follow-up questions]

- Do you find these resources useful for you to learn more about PF?
- Does the summary help you better understand the latest medical research?

## Post-interview survey: evaluate the accessibility of the app

Now I'll give you a questionnarie that include some scale questions [Ask patient why they give certain high/low score in the scale questions]

# Vragenlijst

- 1. Op een schaal van 1 tot 5, hoe gemakkelijk was het om door de verschillende secties en functies van de app te navigeren?
  - 1: Zeer moeilijk
  - 2: Moeiliik
  - 3: Neutraal
  - 4: Gemakkelijk
  - 5: Zeer gemakkelijk
- 2. Beoordeel alstublieft de duidelijkheid van de lay-out en het ontwerp van de app in het begeleiden van u om de gewenste informatie te vinden of taken uit te voeren.
  - 1: Onduidelijk
  - 2: Enigszins onduidelijk
  - 3: Neutraal
  - 4: Enigszins duidelijk
  - 5: Duideliik
- 3. Hoe goed organiseerde en presenteerde de app informatie op een manier die gemakkelijk voor u te begrijpen was?
  - 1: Slecht georganiseerd en moeilijk te begrijpen
  - 2: Enigszins slecht georganiseerd en enigszins moeilijk te begrijpen
  - 3: Neutraal
  - 4: Goed georganiseerd en gemakkelijk te begrijpen
  - 5: Zeer goed georganiseerd en zeer gemakkelijk te begrijpen
- 4. In hoeverre droegen de lettergrootte, kleurcontrasten en algemene visuele presentatie van de app bij aan de toegankelijkheid voor u?
  - 1: Helemaal niet toegankelijk
  - 2: Enigszins ontoegankelijk
  - 3: Neutraal
  - 4: Enigszins toegankelijk
  - 5: Zeer toegankelijk
- 5. Hoe intuïtief was de interface van de app in het begeleiden van u om verschillende taken uit te voeren of functionaliteiten te gebruiken?
  - 1: Helemaal niet intuïtief
  - 2: Enigszins niet intuïtief
  - 3: Neutraal
  - 4: Enigszins intuïtief
  - 5. Zeer intuitief